Esa Kähkönen
Turku University Hospital
21 Papers
68 Citations
Esa Kähkönen is an academic researcher from Turku University Hospital. The author has contributed to research in topics: Prostate cancer & Medicine. The author has an hindex of 10, co-authored 20 publications. Previous affiliations of Esa Kähkönen include University of Turku.
Chat about Author
Papers
In Vivo Imaging of Prostate Cancer Using [68Ga]-Labeled Bombesin Analog BAY86-7548
Esa Kähkönen,Ivan Jambor,Jukka Kemppainen,Kaisa Lehtiö,Tove J. Grönroos,Anna Kuisma,Pauliina Luoto,H. Sipilä,Tuula Tolvanen,Kalle Alanen,Jonna Silén,Markku Kallajoki,Anne Roivainen,Niklaus Schäfer,Roger Schibli,Martina Dragic,Anass Johayem,Ray Valencia,Sandra Borkowski,Heikki Minn +19 more
TL;DR: BAY86-7548 PET/CT is a promising molecular imaging technique for detecting intraprostatic prostate cancer and has a sensitivity, specificity, and accuracy of 88, 81, and 83%, respectively, for detection of primary PCa and sensitivity for metastatic lymph nodes using histology as gold standard.
200
Plasma Pharmacokinetics, Whole-Body Distribution, Metabolism, and Radiation Dosimetry of 68Ga Bombesin Antagonist BAY 86-7548 in Healthy Men
Anne Roivainen,Esa Kähkönen,Pauliina Luoto,Sandra Borkowski,Birte Hofmann,Ivan Jambor,Kaisa Lehtiö,Tuija Rantala,Antje Rottmann,H. Sipilä,Rick Sparks,Sami Suilamo,Tuula Tolvanen,Ray Valencia,Heikki Minn +14 more
TL;DR: Intravenously injected BAY 86-7548 is safe, and rapid metabolism is demonstrated, and the organs with the highest absorbed doses were the urinary bladder wall and the pancreas.
104
Novel biparametric MRI and targeted biopsy improves risk stratification in men with a clinical suspicion of prostate cancer (IMPROD Trial).
Ivan Jambor,Peter J. Boström,Pekka Taimen,Kari T. Syvänen,Esa Kähkönen,Markku Kallajoki,Ileana Montoya Perez,Ileana Montoya Perez,Ileana Montoya Perez,Tommi Kauko,Jaakko Matomäki,Otto Ettala,Harri Merisaari,Harri Merisaari,Harri Merisaari,Aida Kiviniemi,Aida Kiviniemi,Peter B. Dean,Peter B. Dean,Hannu J. Aronen,Hannu J. Aronen +20 more
TL;DR: To evaluate the role of a 3T biparametric magnetic resonance imaging (bpMRI), T2‐weighted imaging, and three separate diffusion‐weighting imaging acquisitions combined with targeted biopsy (TB) for improving risk stratification of men with elevated prostate‐specific antigen (PSA).
80
Validation of IMPROD biparametric MRI in men with clinically suspected prostate cancer: A prospective multi-institutional trial.
Ivan Jambor,Ivan Jambor,Janne Verho,Janne Verho,Otto Ettala,Juha Knaapila,Pekka Taimen,Pekka Taimen,Kari T. Syvänen,Aida Kiviniemi,Aida Kiviniemi,Esa Kähkönen,Ileana Montoya Perez,Marjo Seppänen,Antti Rannikko,Outi Oksanen,Jarno Riikonen,Sanna Mari Vimpeli,Tommi Kauko,Harri Merisaari,Markku Kallajoki,Markku Kallajoki,Tuomas Mirtti,Tarja Lamminen,Jani Saunavaara,Jani Saunavaara,Hannu J. Aronen,Hannu J. Aronen,Peter J. Boström +28 more
TL;DR: In this article, the authors validated a previously developed unique MRI acquisition and reporting protocol, IMPROD biparametric MRI (BPMRI), in men with a clinical suspicion of prostate cancer (PCa) in a multi-institutional trial (NCT02241122).
Prebiopsy multiparametric 3T prostate MRI in patients with elevated PSA, normal digital rectal examination, and no previous biopsy.
Ivan Jambor,Esa Kähkönen,Pekka Taimen,Harri Merisaari,Harri Merisaari,Jani Saunavaara,Kalle Alanen,Branislav Obsitnik,Heikki Minn,Viera Lehotska,Hannu J. Aronen,Hannu J. Aronen +11 more
TL;DR: To find the diagnostic accuracy of 3T multiparametric magnetic resonance imaging (mpMRI) and mpMRI targeted transrectal ultrasound (TRUS)‐guided biopsy using visual coregistration (TB) in patients with elevated prostate‐specific antigen (PSA), normal digital rectal examination, and no previous biopsy, is found.
54